PDGFR beta promotes oncogenic progression via STAT3/STAT5 hyperactivation in anaplastic large cell lymphoma

Varování

Publikace nespadá pod Lékařskou fakultu, ale pod Středoevropský technologický institut. Oficiální stránka publikace je na webu muni.cz.

Autoři	ALONSO I Garces de los Fayos ZUJO L. WIEST I. KODAJOVA P. TIMELTHALER G. EDTMAYER S. ZRIMSEK M. KOLLMANN S. GIORDANO C. KOTHMAYER M. NEUBAUER H A. DEY S. SCHLEDERER M. SCHMALZBAUER B S. LIMBERGER T. PROBST C. PUSCH O. HOGLER S. TANGERMANN S. MERKEL O. SCHIEFER A I. KORNAUTH C. PRUTSCH N. ZIMMERMAN M. ABRAHAM B. ANAGNOSTOPOULOS J. QUINTANILLA-MARTINEZ L. MATHAS S. WOLF P. STOIBER D. STABER P B. EGGER G. KLAPPER W. WOESSMANN W. LOOK T A. GUNNING P. TURNER Suzanne Dawn MORIGGL R. LAGGER S. KENNER L.
Rok publikování	2022
Druh	Článek v odborném periodiku
Časopis / Zdroj	Molecular Cancer
Fakulta / Pracoviště MU	Středoevropský technologický institut
Citace
www	https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-022-01640-7
Doi	http://dx.doi.org/10.1186/s12943-022-01640-7
Klíčová slova	ALCL; PDGFR beta; STAT3; STAT5A; STAT5B; NPM-ALK; Apoptosis
Popis	Background: Anaplastic large cell lymphoma (ALCL) is an aggressive non-Hodgkin T cell lymphoma commonly driven by NPM-ALK. AP-1 transcription factors, cJUN and JUNb, act as downstream effectors of NPM-ALK and transcriptionally regulate PDGFR beta. Blocking PDGFR beta kinase activity with imatinib effectively reduces tumor burden and prolongs survival, although the downstream molecular mechanisms remain elusive. Methods and results: In a transgenic mouse model that mimics PDGFR beta-driven human ALCL in vivo, we identify PDGFR beta as a driver of aggressive tumor growth. Mechanistically, PDGFR beta induces the pro-survival factor Bcl-x(L) and the growth-enhancing cytokine IL-10 via STAT5 activation. CRISPR/Cas9 deletion of both STAT5 gene products, STAT5A and STAT5B, results in the significant impairment of cell viability compared to deletion of STAT5A, STAT5B or STAT3 alone. Moreover, combined blockade of STAT3/5 activity with a selective SH2 domain inhibitor, AC-4-130, effectively obstructs tumor development in vivo. Conclusions: We therefore propose PDGFR beta as a novel biomarker and introduce PDGFR beta-STAT3/5 signaling as an important axis in aggressive ALCL. Furthermore, we suggest that inhibition of PDGFR beta or STAT3/5 improve existing therapies for both previously untreated and relapsed/refractory ALK(+) ALCL patients.